| SEC Form 4 |  |
|------------|--|
| FORM       |  |

1

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| Check this box if no longer subject to<br>Section 16. Form 4 or Form 5<br>obligations may continue. See |
|---------------------------------------------------------------------------------------------------------|
| Instruction 1(b).                                                                                       |

Check this box to indicate that a transaction was made pursuant to a

contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL      |           |  |  |  |  |  |  |  |  |
|-------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number:       | 3235-0287 |  |  |  |  |  |  |  |  |
| Estimated average | burden    |  |  |  |  |  |  |  |  |

hours per response: 0.5

|                                | fy the affirmative<br>ons of Rule 10b5-<br>ction 10. |                   |                                                                                      |                   |                                                                                          |                             |
|--------------------------------|------------------------------------------------------|-------------------|--------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------------------------------|-----------------------------|
| 1. Name and Addre              | ess of Reporting Pers<br>egory <u>M</u>              | on*               | 2. Issuer Name and Ticker or Trading Symbol<br>Centessa Pharmaceuticals plc [ CNTA ] |                   | tionship of Reporting Per<br>all applicable)<br>Director<br>Officer (give title          | 10% Owner<br>Other (specify |
|                                | (First)<br>A PHARMACEU<br>HLEY RD, ALTR              |                   | 3. Date of Earliest Transaction (Month/Day/Year)<br>10/25/2024                       |                   | below)<br>Chief Business                                                                 | below)<br>Officer           |
| (Street)<br>CHESHIRE<br>(City) | X0<br>(State)                                        | WA14 2DT<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)                             | 6. Indiv<br>Line) | vidual or Joint/Group Filin<br>Form filed by One Rep<br>Form filed by More tha<br>Person | orting Person               |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (<br>8) |   |        | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |                                  | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | Indirect (I) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--------------------------------------------|-------------------------------------------------------------|------------------------------|---|--------|----------------------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------|--------------|-------------------------------------------------------------------|
|                                 |                                            |                                                             | Code                         | v | Amount | (A) or<br>(D)                                                        | Price                            | Transaction(s)<br>(Instr. 3 and 4)                                        | (Instr. 4)   | (1150.4)                                                          |
| Ordinary Shares <sup>(1)</sup>  | 10/25/2024                                 |                                                             | <b>S</b> <sup>(2)</sup>      |   | 11,742 | D                                                                    | <b>\$</b> 15.3831 <sup>(3)</sup> | 183,266                                                                   | D            |                                                                   |

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

|                                                     |                                                                       |                                            | (e.g., pt                                                   | 113, 00                      | ans, v | vante                                                  | anto,                     | options, c                                                     |                    | 10 30                   | cunties                                | ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  |                                                                          |                                                                    |
|-----------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------|------------------------------|--------|--------------------------------------------------------|---------------------------|----------------------------------------------------------------|--------------------|-------------------------|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------------------------------------------------------------|--------------------------------------------------------------------|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |        | of<br>Deriv<br>Secu<br>Acqu<br>(A) o<br>Dispe<br>of (D | r<br>osed<br>)<br>r. 3, 4 | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | Amount of<br>Securities |                                        | Amount of Derivative Security (Instr. 5) Derivative Security ( |  | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|                                                     |                                                                       |                                            |                                                             | Code                         | v      | (A)                                                    | (D)                       | Date<br>Exercisable                                            | Expiration<br>Date | Title                   | Amount<br>or<br>Number<br>of<br>Shares |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                          |                                                                    |

## Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2024.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.13 to \$15.60, inclusive. The Reporting Person undertakes to

provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

## Remarks:

/s/ Gregory M. Weinhoff

10/25/2024 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.